Brought to you by 
Chiesi to market uniQure’s Glybera, AMT060 in Europe and other regions; terminated
31 Jul 2017
Executive Summary
Dutch biotech start-up uniQure BV has licensed Italian pharmaco Chiesi Farmaceutici SPA exclusive rights to market its orphan drug Glybera (alipogene tiparvovec) in Europe, Brazil, Mexico, Pakistan, Turkey, Russia, the CIS, and China. Chiesi also received an exclusive license to co-develop uniQure’s Phase I/II hemophilia B gene candidate AMT060 and sell it in the same territories, except China. UniQure retains rights to both medicines in the US, Japan, Australasia, and parts of Latin America and Asia.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Chiesi to market uniQure’s Glybera, AMT060 in Europe and other regions; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice